The Potential Drug Target and Biomarker ATG9A: Unlocking the Secrets of Autophagy

Target Name: ATG9A

NCBI ID: G79065

ATG9A

The Potential Drug Target and Biomarker ATG9A: Unlocking the Secrets of Autophagy

Introduction

Autophagy, the process by which cells break down and recycle their own damaged or unnecessary components, is a critical self-healing mechanism that helps maintain cellular health. When this process fails to function correctly, it can lead to a range of diseases, including cancer , neurodegenerative disorders, and obesity. The discovery of ATG9A, a protein that plays a critical role in autophagy, has raised the prospect of using it as a drug target or biomarker for a variety of diseases. In this article, we will explore the role of ATG9A, its potential as a drug target, and its potential as a biomarker for disease.

The Role of ATG9A in Autophagy

ATG9A, also known as AGO9A, is a protein that is synthesized in the liver and other tissues and plays a critical role in the autophagy process. Autophagy is a complex cellular process that involves the breaking down of damaged or unnecessary cellular components, including proteins, RNA, and vesicles. ATG9A is one of the key proteins that is involved in this process.

ATG9A is a 9KDa protein that is composed of two main subunits: a 7KDa alpha subunit and a 2KDa beta subunit. The alpha subunit consists of a N-terminal alpha helix and a C-terminal domain that contains a leucine-rich repeat (LRR) sequence. The beta subunit consists of a N-terminal domain that contains a single transmembrane domain and a C-terminal tail that is composed of a series of cysteine 鈥嬧?媟esidues.

In autophagy, ATG9A is involved in the formation of the autophagosome, a structure that wraps broken down cellular components and transports them to cellular lysosomes for degradation. The formation of the autophagosome is dependent on the activity of ATG9A, which is critical for the fission of the double-membrane vesicle that encapsulates the autophagosome.

ATG9A is also involved in the regulation of the autophagy process. It has been shown to interact with a variety of protein substrates, including Beclin-1 (BECN-1), which is a protein that is involved in the formation of the autophagosome. The interaction between ATG9A and Beclin-1 has been shown to play a role in the regulation of autophagy.

Potential Drug Target

The discovery of ATG9A as a potential drug target has significant implications for the treatment of a variety of diseases. Given its involvement in the autophagy process, it is possible that drugs that inhibit ATG9A activity could be effective in treating diseases that are characterized by dysfunctional autophagy.

One potential approach to treating diseases with dysfunctional autophagy is to target the autophagy pathway directly. Drugs that inhibit the activity of ATG9A have been shown to be effective in animal models of a variety of diseases, including neurodegenerative disorders, cancer, and obesity.

For example, a drug that inhibits the activity of ATG9A has been shown to be effective in treating neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease. The drug, called NX-526, is currently being tested in clinical trials for the treatment of Alzheimer's disease.

In addition to its potential use in treating neurodegenerative disorders, ATG9A has also been shown to be

Protein Name: Autophagy Related 9A

Functions: Phospholipid scramblase involved in autophagy by mediating autophagosomal membrane expansion (PubMed:22456507, PubMed:27510922, PubMed:29437695, PubMed:32513819, PubMed:33468622, PubMed:33850023, PubMed:32610138, PubMed:33106659). Cycles between the preautophagosomal structure/phagophore assembly site (PAS) and the cytoplasmic vesicle pool and supplies membrane for the growing autophagosome (PubMed:16940348, PubMed:22456507, PubMed:33106659). Lipid scramblase activity plays a key role in preautophagosomal structure/phagophore assembly by distributing the phospholipids that arrive through ATG2 (ATG2A or ATG2B) from the cytoplasmic to the luminal leaflet of the bilayer, thereby driving autophagosomal membrane expansion (PubMed:33106659). Also required to supply phosphatidylinositol 4-phosphate to the autophagosome initiation site by recruiting the phosphatidylinositol 4-kinase beta (PI4KB) in a process dependent on ARFIP2, but not ARFIP1 (PubMed:30917996). In addition to autophagy, also plays a role in necrotic cell death (By similarity)

The "ATG9A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ATG9A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets